Exelixis Eyes Zanzalintinib Breakthrough | Business and Finance News

Exelixis is all-in on zanzalintinib, targeting a third-line colorectal cancer filing soon and advancing six pivotal trials, while cabozantinib continues to drive strong revenue in kidney and neuroendocrine tumors. Built on five strategic pillars—execution, expansion, commercial performance, preparation, and discipline—the company is balancing pipeline growth with disciplined spending, fueled by solid Q2 results and updated guidance. With eyes on a potential colorectal launch and trials expanding into genitourinary and GI cancers, Exelixis remains laser-focused on turning its science into shareholder value and patient impact. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/479418378fb45fba